BioSpace News Archive

Moleculin Biotech announced that its WP1066 drug will receive $2M in private grant funding for its recently announced IND clearance for a physician-sponsored Phase I trial of Moleculin’s drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma.

Clayton will lead Clinical Pharmacology Services and act as the Subject Matter Expert in the Metabolic Sciences offering at HPCTC.

Micell Technologies announced that The Lancet has published data from the DESSOLVE III clinical trial.

Sarah Cannon announced that 28 abstracts authored by members of the Sarah Cannon Blood Cancer Network have been selected by the American Society of Hematology (ASH) for presentation at the upcoming 2017 Annual Meeting & Exposition.

The first child to undergo a successful hand transplant also is the first child in whom scientists have detected massive changes in how sensations from the hands are represented in the brain.

This new facility will be the primary manufacturing center for the Company’s wholly owned subsidiary, CVD Materials Corporation.

Myomo today announced that Roth Capital Partners, the underwriter of Myomo’s follow-on offering, exercised in full its option to purchase 626,250 shares of common stock.

All-cause mortality in patients receiving PREVYMIS was lower compared to placebo at Week 24 post-transplant and at Week 48 post-transplant.

Critical Outcome Technologies announced a change in the previously set date for the Company’s Annual and Special Meeting of Shareholders (the “Meeting”), which was originally scheduled for Thursday, December 7, 2017 at 9:30 a.m. Eastern Standard Time.

The poster presented at SABCS demonstrated that H3B-6545 has a unique mode of ERα antagonism and exhibits superior preclinical anti-tumor activity to fulvestrant in the MCF-7 xenograft model with once daily oral dosing, achieving maximal antitumor activity at doses >10x below the maximum tolerated dose in mice.